TransCode Therapeutics to Host R&D Webcast Highlighting Phase 2a Trial for Metastatic Colorectal Cancer

TransCode Therapeutics (NASDAQ: RNAZ) announced it will host its first live virtual R&D webcast on June 18, 2026, to provide strategic, scientific, and clinical updates across its development pipeline. The presentation will focus on the company’s recently initiated Phase 2a clinical trial of TTX-MC138 in circulating tumor DNA-positive colorectal cancer, a significant step forward for the clinical-stage biopharmaceutical company. The webcast will also include portfolio updates and a discussion of TransCode’s broader investment thesis.

TTX-MC138 is the company’s lead therapeutic candidate, designed to treat metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The Phase 2a trial represents a critical milestone for TransCode, as it moves from preclinical and early-phase studies to more advanced clinical testing in patients with high-risk cancers. Colorectal cancer remains a leading cause of cancer-related deaths worldwide, and the need for effective treatments for metastatic disease is urgent.

In addition to the colorectal cancer program, TransCode is pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. The company has a portfolio of first-in-class therapeutic candidates aimed at mobilizing the immune system to recognize and destroy cancer cells. The webcast will provide investors and stakeholders with a comprehensive overview of these programs and their potential impact on cancer treatment.

The announcement underscores the importance of TransCode’s approach, which targets microRNA-10b, a unique biomarker associated with metastasis. By focusing on this target, the company aims to address a critical unmet need in oncology: the treatment of metastatic disease, which is responsible for the majority of cancer deaths. Success in the Phase 2a trial could position TTX-MC138 as a novel therapy for patients with limited options.

For more details, the full press release is available at https://ibn.fm/u5AfW. The latest news and updates on TransCode Therapeutics can be found in the company’s newsroom at https://ibn.fm/RNAZ.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is TransCode Therapeutics to Host R&D Webcast Highlighting Phase 2a Trial for Metastatic Colorectal Cancer.

The post TransCode Therapeutics to Host R&D Webcast Highlighting Phase 2a Trial for Metastatic Colorectal Cancer appeared first on citybuzz.